Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 17:52 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Sulfasalazine in Treating Painful Neuropathy
NCT01667029 · Massachusetts General Hospital · PHASE2 · terminated · last registry update 2018-08-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “poor enrollment” | – | Registry record, Massachusetts General Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ALOX5 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-05-14Results posted on the registry: University of Nebraska, Leflunomide + Methotrexate-Sulfasalazine-Hydroxychloroquine (NCT00579878)
- 2019-04-18Also stopped (terminated): Christoph Gasche, mesalamine 2400 MG (5-ASA) + mesalamine 1200 MG (NCT03070574)
- 2019-03-26Results posted on the registry: The University of Texas Health Science Center, Houston, Meclofenamic acid + Pentosan polysulfate sodium (NCT02930005)
- 2019-01-29Also stopped (terminated): Annette Langseder, Asacol (NCT00349388)
- 2019-01-15Phase 3 first posted: Guangzhou First People's Hospital, 5-Aminosalicylic acid(5-ASA) and/or Prednisone (NCT03804931)
- 2018-12-10Results posted on the registry: P. Verschueren, Methotrexate + Sulfasalazine (NCT01172639)
- 2018-11-13Results posted on the registry: Hoffmann-La Roche, Azathioprine + Chloroquine (NCT01941095)
- 2018-10-23Phase 3 first posted: Dayanand Medical College and Hospital, Fecal Microbiota Transplantation + Mesalamine Granules (NCT03716388)
- 2018-09-06Phase 3 first posted: Astellas Pharma China, Inc., Peficitinib + Plaebo (NCT03660059)
- 2018-08-08Results posted on the registry: Tillotts Pharma AG, TP05 + Asacol 400 mg (NCT01903252)
- 2018-04-17Results posted on the registry: University of North Carolina, Chapel Hill, Methotrexate (NCT01393405)
- 2018-01-30Phase 3 first posted: University of Nebraska, Methotrexate + Abatacept (NCT03414502)
- 2018-01-30Results posted on the registry: Sanofi, Sarilumab + Sulfasalazine (NCT02373202)
- 2018-01-26Phase 3 first posted: Ferring Pharmaceuticals, Budesonide (6 mg) + Budesonide (9 mg) (NCT03412682)
- 2018-01-19Results posted on the registry: Bausch Health Americas, Inc., Balsalazide Disodium (NCT00486031)
- 2018-01-12Also stopped (terminated): Milton S. Hershey Medical Center, Cimzia + Mesalamine (NCT01696942)
- 2017-12-12Results posted on the registry: National Jewish Health, Mesalamine + Placebo (NCT01088243)
- 2017-10-10Results posted on the registry: Milton S. Hershey Medical Center, Cimzia + Mesalamine (NCT01696942)
- 2017-09-14Phase 3 first posted: Shire, 25 mg Ontamalimab + 75 mg Ontamalimab (NCT03283085)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision